Israel-based medical device maker Medical Surgery Technologies (MST) has completed a $12.5m series C round led by pharmaceutical company Haisco Pharmaceutical Group.
Triventures, SCP Vitalife Partners, Agate Mac Medical Investment, OurCrowd and Jacobs Investment Company also contributed to the round.
Founded in 2005, MST has created an image analytics platform called AutoLap that enables surgeons to conduct minimally invasive procedures with minimal interaction.
As part of the funding commitment, Haisco has gained the exclusive right to distribution of AutoLap in China. MST will use the series C funding to increase its marketing and sales efforts in the US, Europe and China.
Agate, Triventures, SCP and Jacobs provided an undisclosed sum in series B funding for MST in 2013. Triventures, SCP and Jacobs reportedly also invested in MST’s series A round, though MST has not disclosed any further details.
Wang Junmin, chief executive of Haisco, said: “We are delighted to enter the Israeli market with a significant investment in MST.
“We see great potential for AutoLap in China and look forward to applying our know-how and experience in bringing this exciting surgical technology to the China market to the benefit of patients, surgeons and hospitals alike.”